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Abstract
Aims/hypothesis. Type 2 diabetes is not only associ-
ated with hyperglycaemia, but also with disorders of
lipid metabolism. The aim of this study was to investi-
gate the association of triglyceride and non-HDL-cho-
lesterol concentrations with cardiovascular disease in
subjects with normal and abnormal glucose metabo-
lism.
Methods. Subjects were 869 men and 948 women
aged 50 to 75 who participated in the Hoorn Study, a
population-based cohort study that started in 1989.
Glucose metabolism was determined by a 75 g OGTT.
High fasting triglyceride and non-HDL-cholesterol
concentrations were defined as above the median of
the study population.
Results. After 10 years of follow-up, the age- and sex-
adjusted hazard ratios for cardiovascular disease were
1.35 (1.11–1.64) and 1.71 (1.40–2.08) for high tri-
glycerides and high non-HDL-cholesterol, respective-
ly, after mutual adjustment. After stratification for
glucose metabolism status, the hazard ratios for car-
diovascular disease for non-HDL-cholesterol were
1.70 (1.31–2.21) in normal glucose metabolism and
1.56 (1.12–2.18) in abnormal glucose metabolism.
Triglycerides were not a risk factor in subjects with
normal glucose metabolism, with a hazard ratio of
0.94 (0.73–1.22), but in subjects with abnormal glu-
cose metabolism, the hazard ratio for cardiovascular
disease was 1.54 (1.07–2.22). In subjects with abnor-
mal glucose metabolism, the hazard ratio for the com-
bined presence of high triglycerides and non-HDL-
cholesterol was 2.12 (1.35–3.34).
Conclusion. Our data suggest that in people with 
abnormal glucose metabolism, but not in those with
normal glucose metabolism, high triglyceride concen-
tration could be associated with the risk of cardiovas-
cular disease, particularly in people with high non-
HDL-cholesterol. [Diabetologia (2003) 46:910–916]
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Prospective Diabetes Study showed that an increased
concentration of low-density-lipoprotein (LDL)-cho-
lesterol and decreased concentration of high-density-
lipoprotein (HDL)-cholesterol, systolic blood pres-
sure, hyperglycaemia, and smoking are the strongest
risk factors for cardiovascular mortality and morbidity
in patients with Type 2 diabetes [4].
A growing body of evidence now supports the role
of triglyceride concentration as an important risk fac-
tor for cardiovascular disease [5], but different results
have been found in specific subgroups, for instance in
subjects with Type 2 diabetes and in obese, insulin-re-
sistant subjects [6, 7]. High concentrations of triglyce-
rides are typically observed in people with Type 2 dia-
Type 2 (non-insulin-dependent) diabetes is associated
with a two- to four-fold increased risk of cardiovascu-
lar disease [1, 2, 3]. Recently, the United Kingdom
UK). The average of duplicate measurements was used. On
their visit to the research centre, participants were asked to
bring their medication; name and dosages of medicaments
were recorded and coded. Anthropometric data were obtained
from all subjects, wearing light clothes only. BMI and waist-
hip-ratio were calculated by dividing weight by height square,
and waist circumference by hip circumference, respectively.
Cardiovascular history and lifestyle habits, including smoking
and alcohol intake were assessed by questionnaire. We exclud-
ed people with missing data on glucose or lipids (n=18), indi-
viduals using lipid-lowering drugs (n=34) at baseline, individ-
uals with missing morbidity data (n=612), and individuals with
missing cause-specific mortality data (n=32). Consequently,
the study population consisted of 1817 subjects, 869 men and
948 women. The Ethical Review Committee of the VU Uni-
versity Medical Centre approved the Hoorn Study. Informed
consent was obtained from all participants.
Follow-up and definition of cardiovascular disease. In 1995
the population register of Hoorn was checked for the vital sta-
tus of all participants, and since then a prospective registration
was continued. In this study, follow-up data until 1st January
2000 were used. Information about non-fatal cardiovascular
disease was obtained by searching medical records from the 
local hospital of the town of Hoorn; causes of death were ex-
tracted from the medical records of the general practitioner and
the local hospital. Both fatal and non-fatal cardiovascular dis-
ease were coded according to the International Classification
of Diseases (ICD-9) [18]. Cardiovascular disease was defined
as first new cardiovascular event. Non-fatal cardiovascular dis-
ease was defined as coronary heart disease (defined by pro-
longed typical chest pain, ECG changes and enzymes), conges-
tive heart failure, transient ischaemic attack or stroke, or 
peripheral atherosclerotic disease. Fatal cardiovascular disease
was defined as ICD codes 390–459 (‘Diseases of the circulato-
ry system’) or 798 (‘Sudden death, cause unknown’). A com-
puter program was used to classify cardiovascular disease, and
in case of doubt a specialist in internal medicine or a cardiolo-
gist decided about the events. Seventeen subjects (0.7%) were
lost to follow-up. We did not receive information about mor-
bidity from 612 individuals (24.6%), because they did not give
permission to access hospital files or had moved out of the
town of Hoorn. Follow-up duration was calculated from the
date of baseline examinations to date of death, date of first new
cardiovascular event after baseline, date of loss to follow-up,
or to 1st January 2000 in event-free subjects.
Statistical analysis. Firstly, we determined the contribution of
high concentrations of triglyceride and non-HDL-cholesterol
to the development of cardiovascular disease. Furthermore, we
assessed the influence of the combined presence of high or low
concentrations of triglyceride and non-HDL-cholesterol. For
this analysis, subjects were categorized into four groups (2×2)
according to the median values of triglyceride and non-HDL-
cholesterol, i.e. 1.4 mmol/l for men and 1.3 mmol/l for women,
and 5.2 mmol/l for men and 5.3 mmol/l for women, respective-
ly. We chose to create groups on the basis of medians in order
to ‘fill’ the groups with low/high combinations of triglycerides
and non-HDL-cholesterol and vice versa, which are less com-
mon than low/low or high/high combinations. Baseline charac-
teristics are shown as means with standard deviations, but for
triglyceride concentration (skewed data) the median and inter-
quartile ranges are shown. Group differences in continuous
variables were examined using ANOVA; for dichotomous vari-
ables, logistic regression was used. Incidence densities were
calculated on the basis of on person-years of follow-up. With
10 years of follow-up and 408 cases of cardiovascular disease,
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betes. In contrast, total cholesterol and LDL-cholester-
ol concentrations have not been found to differ be-
tween people with and without Type 2 diabetes [8].
Very low-density-lipoprotein (VLDL) and intermedi-
ate-density-lipoprotein (IDL) remnants are triglyce-
ride-rich lipoproteins (TRL) and have been shown to
possess atherogenic properties. It has been proposed
that non-HDL-cholesterol, which includes all choles-
terol in atherogenic lipoprotein particles, such as
LDL, Lp(a), VLDL and IDL, might be a stronger risk
factor for cardiovascular disease than LDL-cholesterol
concentration. In the Quebec Cardiovascular Study,
high apoB, representing LDL, VLDL and IDL, was
associated with a more than two-fold risk of ischaemic
heart disease [9]. High non-HDL-cholesterol could be
particularly relevant in people with Type 2 diabetes
and hypertriglyceridaemia [10, 11, 12, 13, 14]. It has
been proposed that the triglycerides in the non-HDL-
particles could further enhance the atherogenic poten-
tial of these particles [15].
The objectives of this study were to investigate the
association of triglyceride concentrations with subse-
quent cardiovascular disease, in a population-based
prospective cohort study (the Hoorn Study) of men
and women aged 50 to 75 years [16], and to examine
the association of non-HDL-cholesterol concentration
with cardiovascular disease in subjects with low or
high triglyceride concentrations. Finally, to determine
whether these associations differ between subjects
with normal and abnormal glucose metabolism.
Materials and methods
Study cohort and methods. All subjects were participants in the
Hoorn Study, a prospective population-based cohort study of
glucose metabolism and diabetes complications, as described
[16]. Briefly, in 1989, a random sample of 50- to 75-year-old
individuals was taken from the population register of the town
of Hoorn in the Netherlands. Of the 3552 individuals invited to
take part in the study, 2540 participated (71.5%), of whom 56
non-Caucasians were excluded, resulting in 2484 participants
at baseline. A 75g OGTT was carried out in all participants,
except in Type 2 diabetic patients using oral blood glucose
lowering agents or insulin. Four glucose metabolism categories
were defined according to the WHO-99 criteria [17]. Subjects
with impaired glucose metabolism (impaired fasting glucose or
impaired glucose tolerance), or known or newly diagnosed
Type 2 diabetes were grouped together in the ‘abnormal glu-
cose metabolism’ group and compared to subjects with normal
glucose metabolism. Fasting plasma glucose concentration and
2-h post-load plasma glucose concentration were determined
with a glucose dehydrogenase method (Merck, Darmstadt,
Germany). After precipitation of the LDL and VLDL from
fasting blood samples, triglycerides, total cholesterol and
HDL-cholesterol were measured by enzymatic techniques
(Boehringer-Mannheim, Mannheim, Germany). Non-HDL-
cholesterol concentration was defined as the difference be-
tween total cholesterol and HDL-cholesterol concentration.
Systolic and diastolic blood pressure were determined at the
right upper-arm, after 5 min of rest in seated subjects, using a
random-zero sphygmomanometer (Hawksley-Gelman, Lancing,
912 G. Bos et al.: A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol
hazard ratios and 95% CI of baseline triglyceride and non-
HDL-cholesterol concentrations for cardiovascular disease
were obtained from multivariate Cox proportional hazard mod-
els. We first adjusted for age and sex, then for other potentially
confounding variables (i.e. waist-to-hip ratio, hypertension,
prevalent cardiovascular disease, smoking and alcohol con-
sumption). Since triglycerides are strongly associated with fac-
tors of the insulin-resistance syndrome, a multivariate model
was conducted only in the final stratified analyses, because of
risk of over adjustment. Furthermore, we tested for eventual
interaction between triglyceride, non-HDL-cholesterol and
glucose metabolism status by adding a product term to the 
survival models (triglyceride × non-HDL-cholesterol, or trigly-
ceride × non-HDL-cholesterol × (ab)normal glucose metabo-
lism). A p value of less than 0.05 was considered statistically
significant. Statistical analyses were done using SPSS for Win-
dows version 10.1.4.
Results
The baseline characteristics of subgroups classified
on the basis of triglyceride and non-HDL-cholesterol
concentrations are shown (Table 1). Among the sub-
jects with high triglyceride concentrations, there were
more Type 2 diabetic patients and subjects with im-
paired glucose metabolism. High concentration of
non-HDL-cholesterol was associated with prevalent
cardiovascular disease, in both triglyceride catego-
ries.
The hazard ratios of cardiovascular disease were
1.19 and 1.63 for subjects with high triglyceride and
high non-HDL-cholesterol concentrations, respec-
tively, after mutual adjustment. The hazard ratio for
subjects with both high triglyceride and high non-
HDL-cholesterol concentrations was 1.92 (1.50–2.47) 
(Table 2).
Subsequently we studied the eventual differences
in the strength of these associations between people
with normal and abnormal glucose metabolism. In ab-
normal glucose metabolism, but not in normal glu-
cose metabolism, the combined presence of high con-
centration of triglyceride and non-HDL-cholesterol
Table 1. Baseline characteristics of the study population according to triglyceride (TG) and non-HDL-cholesterol levels
Low non-HDLa High non-HDL
Low TGb (n=616) High TG (n=294) Low TG (n=340) High TG (n=567)
Age, y 61.0±7.5 62.4±7.5 61.7±7.1 61.9±7.2
Sex, % male 47 50 49 47
Total cholesterol, mmol/l 5.8±0.7 5.8±0.6 7.4±0.7 7.5±0.9
HDL-cholesterol, mmol/l 1.5±0.4 1.2±0.4 1.4±0.3 1.2±0.3
Triglycerides, mmol/l 1.0 (0.8–1.2) 1.7 (1.5–2.2) 1.1 (0.9–1.3) 2.1 (1.7–2.6)
Non-HDL-cholesterol, mmol/l 4.3±0.6 4.6±0.5 6.0±0.7 6.4±0.9
Hypertensive, % 26 33 29 40
Smoking (Non/Current/Former), % 37/27/36 36/28/36 35/29/36 29/36/35
BMI, kg/m2 25.6±3.2 27.0±3.5 25.8±3.1 27.4±3.5
Waist-to-Hip Ratio 0.87±0.09 0.91±0.09 0.89±0.10 0.92±0.08
Diabetes, % 7 14 4 13
Impaired glucose, % 10 24 13 22
Prevalent cardiovascular disease, % 7 7 9 15
a Cut-off points for non-HDL-cholesterol are 5.2 mmol/l in men and 5.3 mmol/l in women (medians)
b Cut-off points for triglycerides are 1.4 mmol/l in men and 1.3 mmol/l in women (medians)
Table 2. Hazard ratios (95% CI) of cardiovascular disease
(CVD) for triglycerides (TG) and non-HDL-cholesterol
n Cases CVD
Linear
Age- and sex-adjusted
TG (log-transformed) 1817 408 1.82 (1.49–2.24)
Non-HDL 1817 408 1.34 (1.24–1.45)
Mutually adjusteda
TG (log-transformed) 1817 408 1.39 (1.10–1.76) b
Non-HDL 1817 408 1.26 (1.15–1.38) e
Dichotomised
Age- and sex-adjusted
High TGc 861 223 1.35 (1.11–1.64)
High non-HDLd 907 248 1.71 (1.40–2.08)
Mutually adjusteda
High TG 861 223 1.19 (0.98–1.46) e
High non-HDL 907 248 1.63 (1.33–2.01) e
Combined categoriesa
Low non-HDL, low TG 616 100 1
Low non-HDL, high TG 294 60 1.10 (0.80–1.52)
High non-HDL, low TG 340 85 1.53 (1.15–2.04)
High non-HDL, high TG 567 163 1.92 (1.50–2.47)
a Age- and sex-adjusted
b Interaction between triglyceride*non-HDL-cholesterol p=0.65
c Cut-off points for triglycerides are 1.4 mmol/l in men and
1.3 mmol/l in women (medians)
d Cut-off points for non-HDL-cholesterol are 5.2 mmol/l in
men and 5.3 mmol/l in women (medians)
e Interaction between triglyceride*non-HDL-cholesterol p=0.53
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was associated with a two-fold higher incident densi-
ty for cardiovascular disease (Fig. 1). The figure sug-
gests an interaction (effect-modification) between tri-
glyceride concentration and non-HDL-cholesterol
concentration and glucose metabolism, such that in
subjects with abnormal glucose metabolism with a
high non-HDL-cholesterol concentration in particu-
lar, high triglyceride was associated with a higher risk
of cardiovascular disease. However, a test for interac-
tion in the Cox model was not significant (p=0.14). In
normal and abnormal glucose metabolism, non-HDL-
cholesterol concentration was a risk factor for cardio-
vascular disease. Subjects with high non-HDL-cho-
lesterol concentration had a 70% higher cardiovascu-
lar risk than subjects with low non-HDL-cholesterol
concentration, independently of triglyceride concen-
tration (Table 3). A high concentration of triglyceride
was associated with a 50% higher risk of cardiovas-
cular disease in subjects with abnormal glucose me-
tabolism, but not in those with normal glucose metab-
olism. Adjustment for other potential confounders at-
tenuated the observed associations between the trigly-
ceride and non-HDL-cholesterol concentrations and
cardiovascular disease in either group. The combined
presence of high triglycerides and non-HDL-choles-
terol in abnormal glucose metabolism was associated
with risk of cardiovascular disease, with a hazard 
ratio of 1.73. Even adjustment for HDL-cholesterol
did not materially alter the hazard ratio [1.68
(1.01–2.78)] (Fig. 2).
Table 3. Hazard ratios (95% CI) of cardiovascular disease (CVD) for medians of triglycerides (TG) and non-HDL-cholesterol,
stratified for glucose metabolism
Normal glucose metabolism Abnormal glucose metabolism
n Cases CVD n Cases CVD
Dichotomised
Age- and sex-adjusted
High TGa 547 112 1.10 (0.86–1.41) 314 111 1.67 (1.16–2.39)
High non-HDL b 647 153 1.67 (1.30–2.15) 260 95 1.67 (1.20–2.33)
Mutually adjustedc
High TG 547 112 0.94 (0.73–1.22) d 314 111 1.54 (1.07–2.22) d
High non-HDL 647 153 1.70 (1.31–2.21) d 260 95 1.56 (1.12–2.18) d
Multivariate model e
High TG 529 105 0.70 (0.53–0.92) 303 106 1.48 (1.00–2.20)
High non-HDL 629 144 1.54 (1.17–2.03) 253 90 1.20 (0.84–1.71)
Combined categories
Age- and sex-adjusted
Low non-HDL, low TG 509 75 1 107 25 1
Low non-HDL, high TG 181 28 0.96 (0.62–1.48) 113 32 1.03 (0.55–1.93)
High non-HDL, low TG 281 69 1.71 (1.23–2.37) 59 16 1.13 (0.67–1.91)
High non-HDL, high TG 366 84 1.60 (1.17–2.19) 201 79 2.12 (1.35–3.34)
Multivariate model e
Low non-HDL, low TG 497 72 1 105 24 1
Low non-HDL, high TG 173 25 0.69 (0.44–1.10) 109 32 1.38 (0.79–2.41)
High non-HDL, low TG 273 64 1.54 (1.09–2.16) 59 16 1.09 (0.57–2.07)
High non-HDL, high TG 356 80 1.07 (0.77–1.50) 194 74 1.73 (1.06–2.81)
a Cut-off points for triglycerides are 1.4 mmol/l in men and
1.3 mmol/l in women (medians)
b Cut-off points for non-HDL-cholesterol are 5.2 mmol/l in
men and 5.3 mmol/l in women (medians)
c Age- and sex-adjusted
d Interaction between triglyceride*non-HDL-cholesterol*glu-
cose metabolism status p=0.14
e Adjusted for age, sex, waist-to-hip ratio, hypertension, pre-
valent cardiovascular disease, smoking and alcohol consump-
tion
Fig. 1. Cardiovascular disease for combined categories of tri-
glycerides (TG) and non-HDL-cholesterol in subjects with nor-
mal (n=1337) and abnormal glucose metabolism (n=480). Bars
represent unadjusted incidence densities
nant proteins, it could indeed identify more atherogen-
ic lipoproteins than does LDL-cholesterol concentra-
tion alone.
There are several possible explanations for the dis-
crepant contribution of increased triglyceride concen-
trations to cardiovascular risk between persons with
and without abnormal glucose metabolism. High fast-
ing and in particular postprandial concentrations of
triglycerides in subjects with abnormal glucose metab-
olism are due to defective insulin action in the liver
and peripheral tissues [31], resulting in impaired sup-
pression of hepatic VLDL production, reduced lipo-
protein lipase activity and consequently impaired
clearance of triglyceride-rich particles due to competi-
tion for the same pathways. Together these events in
turn will lead to longer circulation of atherogenic tri-
glyceride-rich particles [32]. High triglyceride con-
centration, therefore, could be indicative of a more
atherogenic composition of the non-HDL-cholesterol
particles, for example small dense LDL, especially in
people who have abnormal glucose metabolism [33].
It has been suggested to distinguish “good” and “bad”
hypertriglyceridaemia on the basis of the association
with risk of cardiovascular disease [15]. “Bad” tri-
glycerides were suggested to represent increased con-
centrations of apoC-III on the apoB-containing lipo-
proteins, resulting in a diminished ability of lipopro-
tein lipase to hydrolyse the triglycerides in the parti-
cles, leading to accumulation of atherogenic remnants.
In contrast, the “good” triglyceride “cluster” consti-
tutes of high or normal HDL-cholesterol concentration
and low apoC-III and is not associated with enhanced
cardiovascular risk.
The finding that high triglycerides were protective
in subjects with normal glucose metabolism in the
multivariate model was somewhat unexpected. It
could be that this is a finding in our population by
chance; it could be due to statistical limitations. None
of the other individual risk factors actually caused 
the relative risk of high triglycerides to be protective.
Only when adding them simultaneously, the hazard 
ratio became 0.70. This might be caused by over-
adjustment, which is adjusting for factors that are part
of the causal chain, or it might be true. The remaining
triglycerides could reflect the “good” triglycerides,
rendering LDL large and buoyant, and in HDL-parti-
cles [15]. Besides, we expected to find an interaction
between triglyceride concentration and non-HDL-cho-
lesterol concentration as cardiovascular risk factors in
subjects with abnormal glucose metabolism. However,
when testing for interaction, it turned out to be not sta-
tistically significant (p=0.14). Despite this, we con-
ducted survival analysis in strata of glucose metabo-
lism for reasons based on the mechanism of hyper-
triglyceridaemia in subjects with abnormal glucose
metabolism. Indeed, we found support for this concept
in our data. The fact that the interaction was not statis-
tically significant, possibly due to lack of power.
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Discussion
In this study, we observed that high triglyceride con-
centrations did not contribute independently to cardio-
vascular risk in subjects with normal glucose metabo-
lism, whereas there was a substantially increased risk
in subjects with abnormal glucose metabolism.
There is a large body of evidencing large studies
that triglyceride concentration is a risk factor for car-
diovascular disease for both non-diabetic subjects and
diabetic patients [19, 20, 21, 22, 23, 24, 25]. A recent
meta-analysis of 17 prospective trials with 57,000
subjects also concluded that triglyceride concentration
is a risk factor in non-diabetic subjects [5]. We ob-
served that high triglyceride concentrations are a risk
factor for cardiovascular disease in subjects with ab-
normal glucose metabolism, but only in those with
high non-HDL-cholesterol. This result supports the 
inference that the predictive value of triglycerides 
for cardiovascular risk depends on population and the
lipoprotein profile [26].
Many studies have shown that high serum choles-
terol concentration, especially LDL-cholesterol con-
centration, and low HDL-cholesterol concentration are
risk factors for cardiovascular disease in the general
population [25, 27]. In the Lipid Research Clinics Pro-
gram Follow-up Study, non-HDL-cholesterol concen-
tration was a stronger risk factor for cardiovascular
disease mortality than LDL-cholesterol concentration
[10]. More recently, investigators of the Bypass 
Angioplasty Revascularization Investigation conclud-
ed that non-HDL-cholesterol was a predictor of coro-
nary heart disease [28]. This is in line with findings 
in amongst others the Systolic Hypertension in the 
Elderly Program, where non-HDL-cholesterol concen-
tration was a risk factor for cardiovascular disease in
the elderly population consisting of 4736 men and
women with systolic hypertension [29]. Recently, also
the Strong Heart Study reported that non-HDL-choles-
terol could be useful in predicting cardiovascular risk
in patients with diabetes [30]. Since non-HDL-choles-
terol includes not only LDL-cholesterol, but also cho-
lesterol in potentially atherogenic TRL, notably rem-
Fig. 2. Cardiovascular disease for combined categories of
HDL-cholesterol and non-HDL-cholesterol in subjects with
normal (n=1337) and abnormal glucose metabolism (n=480).
Bars represent unadjusted incidence densities
In this population study, there is a strong correla-
tion between triglyceride and non-HDL-cholesterol
concentrations (Spearman correlation coefficient was
0.48). Since non-HDL-cholesterol, TRL and triglyce-
rides are interrelated, their individual contribution to
the pathological processes of cardiovascular disease
cannot be readily assessed.
In this 10-year follow-up study we were able to
compare the risk of triglyceride concentration and
non-HDL-cholesterol concentration with cardiovascu-
lar disease between subjects with normal and abnor-
mal glucose metabolism in a well-characterized popu-
lation-based cohort study. Diabetic patients and sub-
jects with impaired glucose tolerance were taken to-
gether in the analyses. Earlier studies have shown 
that the adverse lipid profile is similar for subjects
with impaired glucose metabolism and subjects with
newly-diagnosed Type 2 diabetes [34]. Additional 
analyses, in which people with impaired glucose 
metabolism and newly-diagnosed diabetic subjects
were considered separately, yielded similar results
(data not shown). The number of known diabetic sub-
jects (n=68) was too small to be analysed separately.
Exclusion of known diabetic subjects did not alter the
results (data not shown).
A limitation of our study was that 612 subjects had to
be excluded because they did not give permission to ac-
cess hospital files. However, there were no considerable
differences between individuals who were excluded and
the rest of the cohort with respect to cardiovascular risk
factors at baseline (data not shown). In addition, we
analysed the impact of exclusion of prevalent cardiovas-
cular disease. Exclusion of subjects with prevalent car-
diovascular disease at baseline did not alter the results
in normal nor in abnormal glucose metabolism, and in
the overall cohort. All results were similar for fatal and
non-fatal cardiovascular disease (data not shown).
The triglyceride concentration was obtained by a
single-fasting plasma triglyceride sample. Although
there is a considerable intra-individual variation in
fasting triglyceride concentration, in a large epidemio-
logical study, it is still possible to categorize the ma-
jority of the subjects correctly into broad subgroups
with high and low concentrations of triglycerides. It is
expected that a (small) proportion of people who in
general have a mean high concentration are wrongly
classified as low, and vice versa. This would have led
to an underestimation of the real relative risk.
In conclusion, in a prospective population-based
cohort study, we observed that triglyceride concentra-
tion was not a risk factor for cardiovascular disease in
subjects with normal glucose metabolism, whereas tri-
glyceride concentration contributed to cardiovascular
disease risk in subjects with abnormal glucose metab-
olism. We found a strong positive association between
serum non-HDL-cholesterol concentration and future
cardiovascular risk, independent of triglyceride con-
centration. In subjects with abnormal glucose metabo-
lism, the increased risk of triglyceride concentrations
above the median of the population and high concen-
tration of non-HDL-cholesterol associated with risk of
cardiovascular disease seems to be even more explicit
than in subjects with normal glucose metabolism.
Monitoring triglyceride concentrations in people with
abnormal glucose metabolism could contribute to the
cardiovascular risk assessment.
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